113707-75-8

Basic information

• Product Name: (R)-(2-Iodo-1-methyl-ethyl)-carbamic acid benzyl ester
• Synonyms: (R)-(2-Iodo-1-methyl-ethyl)-carbamic acid benzyl ester;Benzyl (1-iodopropan-2-yl)carbamate;(R)-benzyl (1-iodopropan-2-yl)carbamate;(2-Iodo-1-methyl-ethyl)-carbamic acid benzyl ester
• CAS NO: 113707-75-8
• Molecular Formula: C₁₁H₁₄INO₂
• Molecular Weight: 319.13883
• Mol File: 113707-75-8.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (R)-(2-Iodo-1-methyl-ethyl)-carbamic acid benzyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-(2-Iodo-1-methyl-ethyl)-carbamic acid benzyl ester(113707-75-8)
• EPA Substance Registry System: (R)-(2-Iodo-1-methyl-ethyl)-carbamic acid benzyl ester(113707-75-8)

Safety Data

• Hazardous Substances Data: 113707-75-8(Hazardous Substances Data)

Usage

General Description

The chemical (R)-(2-Iodo-1-methyl-ethyl)-carbamic acid benzyl ester is an organic compound with the molecular formula C11H14INO2. It is a benzyl ester of carbamic acid and is commonly used in the synthesis of pharmaceuticals and agricultural chemicals. It has two chiral centers, making it a chiral compound, and its optical rotation is (R). (R)-(2-Iodo-1-methyl-ethyl)-carbamic acid benzyl ester is known for its potential as a versatile building block in the synthesis of various biologically active molecules. However, it is also important to handle this chemical with caution, as it is a potentially hazardous material and can cause irritation to the skin, eyes, and respiratory system if not properly handled.

Upstream product

• 288-32-4 1H-imidazole 
• 61425-27-2 ((R)-2-hydroxy-1-methyl-ethyl)-carbamic acid benzyl ester 
• 603-35-0 triphenylphosphine 
• 113707-74-7 [(2R)-2-(benzyloxycarbonylamino)propyl] 4-methylbenzenesulfonate 

Downstream Products

• 136522-02-6 (2S,5S)-2,5-dimethylpyrrolidine-1-carboxylic acid benzyl ester 
• 113774-91-7 ((R)-1-Methyl-pent-4-enyl)-carbamic acid benzyl ester 
• 142643-60-5 ((R)-1-Methyl-hex-5-enyl)-carbamic acid benzyl ester 

Relevant articles and documents

Protease inhibitors

The present invention provides C1-6alkyl-4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease; and parasitic diseases, including malaria, by administering to a patient in need thereof one or more compounds of the present invention.

Protease inhibitors

The present invention provides methods which use 4-amino-azepan-3-one protease inhibitors of cathepsin S in the treatment of diseases in which cathepsin S is implicated, especially treatment or prevention of autoimmune disease; treatment or prevention of a disease state caused by the formation of atherosclerotic lesions and complications arising therefrom; and diseases requiring inhibition, for therapy, of a class II MHC-restricted immune response, inhibition of an asthmatic response, inhibition of an allergic response, inhibition of immune response against a transplanted organ or tissue, or inhibition of elastase activity in atheroma, and novel compounds for use therewith.